Donor-Specific Anti-HLA Antibodies and Endothelial C4d Deposition-Association with Chronic Liver Allograft Failure

Transplantation

Volumn 99, Issue 9, 2015, Pages 1869-1875

  Iacob, Speranta ^a,b,c   Cicinnati, Vito R ^a,b   Lindemann, Monika ^b   Heinemann, Falko M ^b   Radtke, Arnold ^a   Kaiser, Gernot M ^b   Kabar, Iyad ^a   Schmidt, Hartmut H J ^a   Baba, Hideo A ^b   Beckebaum, Susanne ^a,b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C4D; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; HLA CLASS I ANTIBODY; HLA CLASS II ANTIBODY; MYCOPHENOLATE MOFETIL; UNCLASSIFIED DRUG; ALLOANTIBODY; BIOLOGICAL MARKER; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; HLA ANTIGEN; PEPTIDE FRAGMENT;

ADULT; AGE; ARTICLE; BILIARY TRACT DISEASE; BLOOD SAMPLING; CHRONIC GRAFT REJECTION; CHRONIC LIVER FAILURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DONOR AGE; ENDOTHELIUM CELL; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REINFECTION; RISK FACTOR; ADVERSE EFFECTS; BIOPSY; BLOOD; HUMORAL IMMUNITY; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; TIME; TREATMENT FAILURE;

ADULT; BIOLOGICAL MARKERS; BIOPSY; COMPLEMENT C4B; CROSS-SECTIONAL STUDIES; ENDOTHELIAL CELLS; FEMALE; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; IMMUNOHISTOCHEMISTRY; ISOANTIBODIES; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE;

EID: 84943658651     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000613     Document Type: Article

References (52)

1. Ekong UD. The long-term liver graft and protocol biopsy: do we want to look? What will we find? Curr Opin Organ Transplant 2011;16(5):505.
2. Dorje C, Midtvedt K, Holdaas H, et al. Early versus late acute antibodymediated rejection in renal transplant recipients. Transplantation 2013; 96(1):79.
3. Thammanichanond D, Ingsathit A, Mongkolsuk T, et al. Pre-transplant donor specific antibody and its clinical significance in kidney transplantation. Asian Pac J Allergy Immunol 2012;30(1):48.
4. Wiebe C, Nickerson P. Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant 2013;18(4):470.
5. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant. Am J Transplant 2011;11(9):1868.
6. Fedrigo M, Gambino A, Benazzi E, et al. Role of morphologic parameters on endomyocardial biopsy to detect sub-clinical antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30(12):1381.
7. Golocheikine A, Nath DS, Basha HI, et al. Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients. J Heart Lung Transplant 2010;29(4):410.
8. Takeda A, Otsuka Y, Horike K, et al. Significance of C4d deposition in antibody-mediated rejection. Clin Transplant 2012;26(Suppl 24):43.
9. Colvin RB. C4d in liver allografts: a sign of antibody-mediated rejection? Am J Transplant 2006;6(3):447.
10. Schmeding M, Dankof A, Krenn V, et al. C4d in acute rejection after liver transplantation-A valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006;6(3):523.
11. Kozlowski T, Andreoni K, Schmitz J, Hayashi PH, Nickeleit V. Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012;18(6):641.
12. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011;17(4):357.
13. Watson R, Kozlowski T, Nickeleit V, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006;6(12):3022.
14. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011;11(3):500.
15. Oudshoorn M, Horn PA, Tilanus M, Yu N. Typing of potential and selected donors for transplant: methodology and resolution. Tissue Antigens 2007;69(Suppl 1):10.
16. Heinemann FM. HLA genotyping and antibody characterization using the luminex multiplex technology. Transfus Med Hemother 2009;36 (4):273.
17. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19(12):1409.
18. O'Leary JG, Klintmalm GB. Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant 2013;18(3):279.
19. Ruiz R, Tomiyama K, Campsen J, et al. Implications of a positive crossmatch in liver transplantation: a 20-year review. Liver Transpl 2012; 18(4):455.
20. Perera M, Silva M, Murphy N, Briggs D, Mirza D, Neil D. Influence of preformed donor-specific antibodies and C4d on early liver allograft function. Scand J Gastroenterol 2013;48(12):1444.
21. Mizutani K, Terasaki P, Rosen A, et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005;5(9):2265.
22. DeVos JM, Patel SJ, Burns KM, et al. De novo donor specific antibodies and patient outcomes in renal transplantation. Clin Transpl 2011:351.
23. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013;95(3):410.
24. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012;12(5):1157.
25. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013;13(6):1541.
26. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012;18(11):1333.
27. Goh A, Scalamogna M, De Feo T, Poli F, Terasaki PI. Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl 2010;16(3):308.
28. Fontana M, Moradpour D, Aubert V, Pantaleo G, Pascual M. Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int 2010; 23(8):858.
29. Ntokou IS, Iniotaki AG, Kontou EN, et al. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Transpl Int. 2011;24(11):1084.
30. O'Leary JG, Kaneku H, Jennings LW, et al. Preformed class II donorspecific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013;19(9):973.
31. Yamada H, Kondou H, Kimura T, et al. Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation. Pediatr Transplant 2012;16(8):858.
32. Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin Liver Dis 2009;29(1):91.
33. Steinhoff G. Major histocompatibility complex antigens in human liver transplants. J Hepatol 1990;11(1):9.
34. Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int 2012;81(7):628.
35. Martelius T, Halme L, Arola J, Hockerstedt K, Lautenschlager I. Vascular deposition of complement C4d is increased in liver allografts with chronic rejection. Transpl Immunol 2009;21(4):244.
36. Bouron-Dal Soglio D, Rougemont AL, Herzog D, Soucy G, Alvarez F, Fournet JC. An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases. Hum Pathol 2008;39(7):1103.
37. O'Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl 2014;20(6):655.
38. Iacob S, Cicinnati VR, Hilgard P, et al. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation 2007;84(1):56.
39. Rentenaar RJ, van Diepen FN,Meijer RT, et al. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int 2002;62(1):319.
40. Dalal P, Grafals M, Chhabra D, Gallon L. Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection. Ther Clin Risk Manag 2009;5(1):139.
41. Sun Q, Liu ZH, Yin G, et al. Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients. Nephrol Dial Transplant 2006;21(2):510.
42. Sun Q, Tang Z, Chen J, Chen H, Liu Z, Li L. Late developing C4d-positive humoral renal allograft rejection associated with withdrawal of mycophenolate mofetil. Transplant Proc 2005;37(10):4244.
43. Cicinnati VR, Hou J, Lindemann M, et al. Mycophenolic acid impedes the antigen presenting and lymph node homing capacities of human blood myeloid dendritic cells. Transplantation 2009;88(4):504.
44. Bahra M, Neumann UI, Jacob D, et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant 2005;5(2):406.
45. Jiang S, Tang Q, Rong R, et al. Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. Eur J Pharmacol 2012;688(1-3):56.
46. Manzia TM, Angelico R, Toti L, et al. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl Int 2011;24(5):461.
47. Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007;321(2):583.
48. Beckebaum S, Klein CG, SotiropoulosGC, et al. Combinedmycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study. Transplant Proc. 2009;41(6):2567.
49. Cicinnati VR, Yu Z, Klein CG, et al. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients-assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther 2007;26(9):1195.
50. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005;11(7):750.
51. McCaughan GW, Zekry A. Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation. Liver Transpl 2003;9(11):S21.
52. Morath C, Zeier M. Review of the antiproliferative properties of mycophenolatemofetil in non-immune cells. Int J Clin Pharmacol Ther 2003;41(10):465.